Is pazopanib (Viant) a tyrosine kinase inhibitor and its mechanism of action

Pazopanib (Pazopanib) is an oral small molecule tyrosine kinase inhibitor (TKI), which mainly targets the vascular endothelial growth factor receptor (VEGFRVEGFR pan>), platelet-derived growth factor receptor (PDGFR) and stem cell factor receptor (c-KIT) and other targets. By inhibiting the tyrosine kinase activity of these receptors, pazopanib can interfere with tumor angiogenesis, thereby blocking the nutrient supply and growth signals of tumor cells, thereby inhibiting tumor proliferation and spread.

The mechanism of action of pazopanib is mainly through inhibiting the VEGFR family receptor signaling pathway and blocking the formation of new blood vessels. Tumor tissue relies on new blood vessels to provide oxygen and nutrients to maintain rapid proliferation, and VEGFR plays a central role in the angiogenesis process. By inhibiting the kinase activity of VEGFR, pazopanib can reduce the proliferation and migration of vascular endothelial cells, thereby inhibiting the formation of tumor vascular networks and reducing the chance of tumor growth and metastasis.

In addition, pazopanib also acts on targets such as PDGFR and c-KIT to further enhance the anti-tumor effect. PDGFR plays a role in tumor stromal cell proliferation and vascular homeostasis regulation, while c-KIT plays an important role in the growth and survival of certain tumor cells. Through multi-target effects, pazopanib not only inhibits tumor angiogenesis, but also directly interferes with tumor cell proliferation signals, thereby improving the therapeutic effect.

In clinical application, pazopanib is used in the treatment of advanced renal clear cell carcinoma (RCC) and locally advanced or metastatic soft tissue sarcoma (STS). Its tyrosine kinase inhibitory effect makes it an important option for targeted therapy, especially in patients who are inoperable or have poor tolerance to other chemotherapy regimens. At the same time, attention should be paid to liver function monitoring, blood pressure control and cardiovascular risk management during use to ensure the safety and efficacy of treatment.

Reference link:https://www.drugs.com